Abstracts tagged "ANCA associated vasculitis"

Abstract Number: 0717 • ACR Convergence 2024
Associations Between Calendar Time and Age at Diagnosis with Mortality in a National Cohort of Veterans with ANCA-Associated Vasculitis from 2001-2020
Jennifer Hanberg¹, Svetlana Eden², Amy Anderson-Mellies², Suman Kundu², Matthew Freiberg², Zachary Wallace³ and Evelyn Hsieh⁴, and the Veterans Aging Cohort Study Project Team, ¹Brigham and Women's Hospital, Boston, MA, ²Vanderbilt University Medical Center and Tennessee Valley VA, Nashville, TN, ³Massachusetts General Hospital, Newton, MA, ⁴Yale School of Medicine / VA Connecticut Healthcare System, West Haven, Connecticut, New Haven, CT
Background/Purpose: It is not clear whether advances in ANCA-associated vasculitis (AAV) management between 2001-2020 have translated to improvement in population-level outcomes, including among older adults.…
Abstract Number: 0824 • ACR Convergence 2024
The Effect of Intranasal Niclosamide on Nasal Symptoms in Patients with ENT Manifestations of ANCA-Associated Vasculitis (AAV): Post Hoc Analysis of Subset of Patients Recruited to the PROTECT-V Trial
Benjamin Lim¹, Wendi Qian¹, Francis Dowling², Michael Chen-Xu¹, Alan Salama³ and Rona Smith⁴, ¹University of Cambridge, Cambridge, ²Cambridge University Hospitals NHS Foundation Trust, Cambridge, ³University College London, London, ⁴University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Ear, nose and throat (ENT) manifestations are common in ANCA associated vasculitis (AAV), particularly the PR3 (proteinase 3) sub type. There is unmet need…
Abstract Number: 1603 • ACR Convergence 2024
Antineutrophil Cytoplasmic Autoantibody Levels in Patients in the Avacopan Phase 3 Trial
Frank B. Cortazar¹, Duvuru Geetha², Salem Almaani³, Christina Song⁴, Tomasz M. Wilmanski⁴, Alana M. Bozeman⁴, Peter Merkel⁵ and David Jayne⁶, and ADVOCATE Study Group, ¹New York Nephrology Vasculitis and Glomerular Center, Saint Peter’s Hospital-Albany, Albany, NY, ²Johns Hopkins University, Baltimore, MD, ³The Ohio State University Medical Center, Columbus, OH, ⁴Amgen Inc., Thousand Oaks, CA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶University of Cambridge, Cambridge, United Kingdom
Background/Purpose: The utility of measuring serial antineutrophil cytoplasmic autoantibody (ANCA) levels to guide treatment in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) is controversial.…
Abstract Number: 2188 • ACR Convergence 2024
Parent Verses Patient Perspectives of Health-Related Quality of Life Among Children with Vasculitis
Clare Peckenpaugh¹, Aimee Hersh², Sara Stern², Erin Treemarcki², Peter Merkel³ and Karen James², ¹University of Utah Department of Pediatrics, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Vasculitis is a group of chronic, relapsing diseases that can lead to significant morbidity due to both disease and treatment, impacting patients’ health related…
Abstract Number: 2495 • ACR Convergence 2024
Diffuse Alveolar Hemorrhage in Patient with ANCA-associated Vasculitis AndInterstitial Lung Disease
Elif Ediboglu¹, Samuel Falde¹, Misbah Baqir¹, Rodrigo Cartin-Ceba² and Ulrich Specks¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Scottsdale, AZ
Background/Purpose: The association of interstitial lung disease (ILD) and microscopic polyangiitis (MPA) is increasingly recognized. The implications of ILD as it relates to clinical outcomes…
Abstract Number: 0718 • ACR Convergence 2024
Incidence and Patient Profile Changes in ANCA-Associated Vasculitis Following the SARS-CoV-2 Pandemic
Laura Ramos Ortiz de Zarate¹, Aresio Plaza Lopez², Alejandro mARTINEZ rODADO³, Maria Machattou¹, Pablo Navarro Palomo⁴, maria alonso de francisco³, Carlota Navarro Joven³, Natalia de la Torre-Rubio⁴, Olga Rusinovich⁵, Carolina Merino⁶, Blanca García Magallón⁷, Jose Campos Esteban⁷, hildegarda Godoy Tundidor⁸, Mónica Fernández Castro⁹, JESUS SANZ SANZ⁴, Carmen Barbadillo Mateos⁷, Carlos Maria Isasi Zaragoza⁷, Andrea Liso Andrino⁷, Maria Concepcion Sanchez Fernandez³ and Jose Luis Andreu⁴, ¹Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Spain, ²Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ³Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Madrid, Spain, ⁴Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain, ⁵Hospital Universitario Puerta de Hierro Majadahonda., Boadilla del Monte, Spain, ⁶Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, ⁷Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Majadahonda, Madrid, Spain, ⁸Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Madrid, Spain, ⁹Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Madrid, Spain
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is often linked to previous viral infections. Clinical evidence suggests SARS-CoV-2 virus may follow a similar pattern, with an…
Abstract Number: 0825 • ACR Convergence 2024
Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator (BRAVO): 6-month Outcomes of a Longitudinal Cohort Study
Arielle Mendel¹, Lillian Barra², Sasha Bernatsky³, Alison Clifford⁴, Mojtaba Dabaghjamanesh⁵, Natasha Dehghan⁶, Aurore Fifi-Mah⁷, Jean-Paul Makhzoum⁸, Rosalie-Sélène Meunier⁹, Nataliya Milman¹⁰, Medha Soowamber¹¹, Jan Willem Cohen Tervaert¹², Elaine Yacyshyn⁴, Nader Khalidi¹³ and Christian Pagnoux¹⁴, ¹McGill University Health Centre, Montreal, QC, Canada, ²Western University, London, ON, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Western University, Canada, Richmond Hill, ON, Canada, ⁶University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁹Hôpital Sacré-Coeur, Université de Montréal, Montreal, QC, Canada, ¹⁰the Ottawa Hospital, Ottawa, ON, Canada, ¹¹Mount Sinai Hospital, Woodbridge, ON, Canada, ¹²University of Alberta, Edmonton, Canada, ¹³McMaster University, Hamilton, ON, Canada, ¹⁴Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: To evaluate the effectiveness and safety of rituximab (RTX) biosimilars compared to the originator in Canadians with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis…
Abstract Number: 1604 • ACR Convergence 2024
Utilizing Machine Learning with Claims Data to Diagnose and Quantify the Prevalence of Eosinophilic Granulomatosis with Polyangiitis
Peter Merkel¹, Peter Baudy², Donna Carstens², Benjamin North³, Mahvish Danka³, Stephanie Roy³, Hanna Marshall³ and Geoffrey Chupp⁴, ¹University of Pennsylvania, Philadelphia, PA, ²Respiratory & Immunology US Medical, AstraZeneca, Wilmington, ³IQVIA, Philadelphia, ⁴School of Medicine, Yale University, New Haven
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis that can present indolently. This can lead to a delay in diagnosis and treatment. This study…
Abstract Number: 2478 • ACR Convergence 2024
Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial
Christian Pagnoux¹, Antoine Neel², Sarah Bray³, Rachel E. Gurlin⁴, Darcy Trimpe⁵, David Jayne⁶ and Peter Merkel⁷, and ADVOCATE Study Group, ¹Mount Sinai Hospital, Toronto, ON, Canada, ²Department of Internal Medicine, CHU Nantes, Nantes, France, ³Amgen Ltd, Cambridge, United Kingdom, ⁴Amgen Inc., Mountain View, CA, ⁵Amgen Inc., Thousand Oaks, CA, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are subtypes of ANCA-associated vasculitis that frequently involve the kidneys. However, a subset of patients with…
Abstract Number: 2496 • ACR Convergence 2024
Clinical Features and Outcomes of Hydralazine-associated Vasculitis: A Case-Control Study
Elif Ediboglu¹, Samuel Falde¹, Misbah Baqir¹, Rodrigo Cartin-Ceba² and Ulrich Specks¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Scottsdale, AZ
Background/Purpose: We aimed to investigate the relationship between hydralazine and any form of vasculitis (small, medium, or large vessel), to describe clinical features and outcomes…
Abstract Number: 0722 • ACR Convergence 2024
Factors Associated with Relapses and Performance of the French Vasculitis Study Group Relapse Score in a Cohort of Mexican Patients with ANCA-Associated Vasculitis
Andrea Hinojosa-Azaola¹, Marlon Sandino-Bermúdez², Ana Sarahí Mulia-Soto³, Juan M. Mejía-Vilet⁴ and Eduardo Martin Nares⁵, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Distrito Federal, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Ciudad de México, Mexico, ⁴Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ⁵Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Anti-neutrophil cytoplasm antibody-associated vasculitis (AAV) encompass a group of systemic inflammatory diseases with multi-organ involvement. Relapses occur in 14-44% of patients within 18-36 months…
Abstract Number: 0826 • ACR Convergence 2024
Plasma Exchange for Severe Alveolar Hemorrhage in ANCA-Associated Vasculitis: Emulation of a Target Trial
Anne-Claire Sanna¹, Ségolène Gendreau², Cyrielle Desnos³, Dimitri Titeca-Beauport⁴, Jolan Malherbe⁵, Florian Reizine⁶, Kladoum Nassarmadji⁷, Louis Guillaume⁸, Alban Deroux⁹, Eddine Bendiab¹⁰, Jennifer Catano¹¹, Julien Campagne¹², Marc Pineton de Chambrun¹³, Valentin Coirier¹⁴, Clara Vigneron¹¹, Maxime SAMSON¹⁵, Antoine Neel¹⁶, Benoît Brilland¹⁷, Jean-Philippe Martellosio¹⁸, Maxim Desgrouas¹⁹, Olivier Simon²⁰, Perrine SMETS²¹, Romain Paule²², Stanislas Faguer²³, Stéphane Giorgiutti²⁴, Thylbert Deltombe²⁰, François Arrive¹⁸, Ingrid Masson²⁵, Thomas Quemeneur²⁶, Cécile Audrey Durel²⁷, Etienne de Montmollin¹¹, François Perrin²⁸, Herve Lobbes²⁹, Quentin Lajoye³⁰, Rafik Mesbah³¹, Rodéreau Outh³², Adeline Lacraz³³, Damien Contou³⁴, Fabien Parazols³⁵, Florian Garo³⁶, Grégoire Ducoux³⁷, Halil Yildiz³⁸, Isabelle Rey³⁹, Viviane Queyrel⁴⁰, Rita Eid¹¹, Robin Arcani⁴¹, Xavier Puéchal⁴², Raphael Porcher⁴³, Nicolas de Prost¹¹ and Benjamin Terrier⁴⁴, and French Vasculitis Study Group (FVSG); Groupe de Recherche en Réanimation Respiratoire du patient d'Onco-Hématologie (GrrrOH), ¹Cochin Hospital, Paris, France, ²Mondor Hospital, Paris, ³Tenon Hospital, Paris, France, ⁴CHU Amiens, Amiens, France, ⁵CHU Caen, Caen, France, ⁶CHU Vannes, Vannes, ⁷APHP, Paris, ⁸Hopital de Metz, Metz, France, ⁹Clinique Universitaire de Médecine Interne, Department of Internal Medicine, Grenoble University Hospital, Grenoble, France, ¹⁰CHU Montpellier, Montpellier, France, ¹¹APHP, Paris, France, ¹²Hôpital Robert Schuman - Competence center for autoimmune diseases, Internal Medicine, Metz, France, ¹³Sorbonne Université, Paris, France, ¹⁴CHU Rennes, Rennes, France, ¹⁵Dijon University Hospital, Dijon, France, ¹⁶Department of Internal Medicine, CHU Nantes, Nantes, France, ¹⁷CHU Angers, Angers, France, ¹⁸CHU Poitiers, Poitiers, France, ¹⁹CHU Orléans, Orleans, France, ²⁰CHU Réunion, Réunion, France, ²¹Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ²²Foch Hospital, Suresnes, France, ²³CHU Toulouse, Toulouse, France, ²⁴CHRU Strasbourg, Strasbourg, France, ²⁵CHU Saint Etienne, Saint Etienne, France, ²⁶CH Valenciennes, Valenciennes, France, ²⁷HCL, Lyon, France, ²⁸CH Saint Nazaire, Saint Nazaire, France, ²⁹CHU Clermont-Ferrand, Clermont-Ferrand, France, ³⁰CHU Bordeaux, Bordeaux, France, ³¹CH Boulogne, Boulogne, France, ³²CH, Perpignan, France,, Perpignan, France, ³³CH Bayonne, Bayonne, France, ³⁴CH Argenteuil, Argenteuil, France, ³⁵CH Perpignan, Perpignan, France, ³⁶CHU Nimes, Nimes, France, ³⁷CHU Lyon, Lyon, France, ³⁸Université de Louvain, Louvain, Belgium, ³⁹CH Annecy, Annecy, France, ⁴⁰CHU Nice, Nice, France, ⁴¹APHM, Marseille, France, ⁴²National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ⁴³Department of Rheumatology, Bicêtre AP-HP Hôpital, Université Paris-Saclay, Paris, Ile-de-France, France, ⁴⁴Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Mortality is high in patients with diffuse alveolar hemorrhage (DAH) associated with ANCA-associated vasculitis (AAV). In the PEXIVAS study, plasma exchange (PLEX) did not have a…
Abstract Number: 1605 • ACR Convergence 2024
Characteristics of Relapses in Patients with Eosinophilic Granulomatosis with Polyangiitis
Peter Merkel¹, David Jayne², Ulrich Specks³, Christian Pagnoux⁴, Parameswaran Nair⁵, Nader Khalidi⁵, Arnaud Bourdin⁶, Lena Börjesson Sjö⁷, Sofia Necander⁷, Anat Shavit⁸, Claire Walton⁹ and Michael Wechsler¹⁰, ¹University of Pennsylvania, Philadelphia, PA, ²University of Cambridge, Cambridge, United Kingdom, ³Mayo Clinic, Rochester, MN, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵McMaster University and St Joseph’s Healthcare, Hamilton, ON, Canada, ⁶Department of Respiratory Diseases, University of Montpellier, CHU Montpellier, PhyMedExp, INSERM, CNRS, Montpellier, France, ⁷Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁸BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ⁹Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁰National Jewish Health, Denver, CO
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by asthma, eosinophilia, and small-to-medium size vessel vasculitis. In the Phase 3, double-blind,…
Abstract Number: 2479 • ACR Convergence 2024
Mepolizumab Treatment Decreased Oral Corticosteroid Use and Improved Clinical Response, Control Status, and Remission in Patients with Eosinophilic Granulomatosis with Polyangiitis: Results up to 24 Months from a Large Network of US Allergy Practices
Michael E Wechsler¹, Anna Kovalszki², Jared Silver³, Brian Stone⁴, Lior Seluk⁵, Lynn Huynh⁶, Wilson da Costa Junior⁶, Mingchen Ye⁶, Jeremiah Hwee⁷, Mei Sheng Duh⁶, William McCann⁴ and Amy G. Edgecomb⁸, ¹Department of Medicine, National Jewish Health, Denver, CO, ²Division of Allergy and Clinical Immunology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ³US Medical Affairs - Respiratory, GSK, Durham, ⁴Allergy Partners, Asheville, NC, ⁵Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, ⁶Analysis Group, Boston, MA, ⁷Value Evidence and Outcomes, GSK, Mississauga, Canada, ⁸US Value, Evidence, & Outcomes, Anti-Infectives and Respiratory, GSK, Philadelphia
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a severe rare systemic inflammatory disease characterized by elevated blood eosinophil counts ≥1000 cells/µL and vasculitis of small-…
Abstract Number: 2497 • ACR Convergence 2024
Clinical Characteristics and Outcomes of Hydralazine-induced ANCA-associated Vasculitis. a Single Center Retrospective Cohort Analysis from the US
Muhammad Shamim¹, Mazen Allouni², Haseeb Chaudhary³, Ansaam Daoud⁴, Loai Dweik⁵, Hashim Syed⁶ and Omer Pamuk⁷, ¹University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ²Case Western Reserve, University Hospitals, Cleveland Medical Center, Cleveland, OH, ³Case Western Reserve University, Westlake, OH, ⁴Case Western Reserve University/University Hospitals, Akron, OH, ⁵Cleveland Clinic Akron General Internal Medicine, Akron, OH, ⁶Case Western/ UH, Cleveland, ⁷University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Hydralazine-induced ANCA-associated vasculitis (HIAAV) is a rare clinical problem. There is paucity of data regarding clinical features, treatment, and prognosis of hydralazine-induced AAV in…

« Previous Page
1
…
3
4
5
6
7
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].